$KPRX News

Kiora Pharmaceuticals Obtains Exclusive Development And Commercialization Rights, Outside Asia, To KIO-401 From Senju Pharmaceutical For Central Retinal Artery Occlusion For $3.5M In Upfront Payment And $285M In Additional Milestones And Royalties-8K Filing

Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model

Kiora Pharmaceuticals Released Preclinical Data Showing That KIO-300 Significantly Suppressed Seizure-associated Electrophysiological Activity In An Ex Vivo Temporal Lobe Epilepsy Model

Kiora Pharmaceuticals Files Prospectus For Offering 11.797M Common Stock On Behalf Of Selling Shareholders

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

Kiora Pharmaceuticals Q1 EPS $(0.58) Beats $(0.71) Estimate

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline

Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors

Kiora Pharmaceuticals shares are trading higher after the company announced it will sell up to 438,471 shares in a private placement.

Kiora Pharmaceuticals shares are trading higher after the company announced it will sell up to 438,471 shares in a private placement.

Kiora Pharmaceuticals Entered Securities Purchase Agreement On April 3, 2026; To Issue 438,471 Shares Of Common Stock In Private Placement

Kiora Pharmaceuticals Announces Management Team Changes

Kiora Pharmaceuticals Q4 EPS $(1.60) Misses $(0.67) Estimate

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference